Centrient Pharmaceuticals joins UNGC
Reinforcing commitment to ethical and sustainable growth
Reinforcing commitment to ethical and sustainable growth
The agreement complements other PPAs for Sandoz production sites globally
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Subscribe To Our Newsletter & Stay Updated